Reading SNDX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SNDX free→Reading SNDX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SNDX free→QuarterlyIQ Insights · SNDX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
of this Current Report on Form 8-K is incorporated herein by reference. The Company offered and sold the Notes to certain investors in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”). The Company relied on this exemption from registration based in part on representations made by each investor in the subscription agreements, dated June 3, 2026, between the Company and each investor identified therein. Th…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the Syndax Pharmaceuticals, Inc. (the “ Company ”) 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”), the Company’s stockholders approved the Company’s 2026 Equity Incentive Plan (the “ 2026 Plan ”), which the Board of Directors of the Company (the “ Board ”) previously approved, subject to stockholder approval at the Annual Meeting.…
Unregistered Sale of Equity Securities. The information set forth under
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
Unregistered Sale of Equity Securities. The information set forth under
Entry into a Material Agreement. Indenture and Notes On June 3, 2026, Syndax Pharmaceuticals, Inc. (the “ Company ”) entered into privately negotiated subscription agreements (the “ Subscription Agreements ”) with certain investors, pursuant to which the Company will issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (the “ Notes ”). The Notes will be issued pursuant to an indenture (the “ Indenture ”), between the Company and U.S. Bank Trust Company, N…
Importance-ranked changes since the prior daily snapshot.
Company momentum rose by 14.9 points (from 20.4 to 35.3).
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.